84. サルコイドーシス Sarcoidosis Clinical trials / Disease details


臨床試験数 : 149 薬物数 : 227 - (DrugBank : 81) / 標的遺伝子数 : 82 - 標的パスウェイ数 : 167

  
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-010714-30-IT
(EUCTR)
18/01/201011/12/2009A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis - ND Chronic sarcoidosis
MedDRA version: 9.1;Level: LLT;Classification code 10039486
Product Name: Ustekinumab
Product Code: CNTO1275
Product Name: Golimumab
Product Code: CNTO148
CENTOCORNULLNot RecruitingFemale: yes
Male: yes
180Phase 2United Kingdom;Germany;Netherlands;Denmark;Belgium;France;Italy
2EUCTR2009-010714-30-NL
(EUCTR)
22/12/200903/02/2011A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis - Chronic sarcoidosis
MedDRA version: 9.1;Level: LLT;Classification code 10039486;Term: Sarcoidosis
Product Name: Golimumab Liquid in prefilled syringe
Product Code: CNTO 148
INN or Proposed INN: golimumab
Other descriptive name: human anti TNF-alpha monoclonal antibody
Product Name: ustekinumab liquid in prefilled syringe
Product Code: CNTO1275
INN or Proposed INN: ustekinumab
Other descriptive name: human anti-IL 12/23 monoclonal antibody
Centocor BVNULLNot RecruitingFemale: yes
Male: yes
180Phase 2United Kingdom;Germany;Netherlands;Denmark;Belgium;France;Italy
3EUCTR2009-010714-30-FR
(EUCTR)
10/11/200915/10/2009A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic SarcoidosisA Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis Chronic sarcoidosis
MedDRA version: 9.1;Level: LLT;Classification code 10039486;Term: Sarcoidosis
Product Name: Golimumab Liquid in prefilled syringe
Product Code: CNTO 148
INN or Proposed INN: golimumab
Other descriptive name: human anti TNF-alpha monoclonal antibody
Product Name: ustekinumab liquid in prefilled syringe
Product Code: CNTO1275
INN or Proposed INN: ustekinumab
Other descriptive name: human anti-IL 12/23 monoclonal antibody
Centocor BVNULLNot RecruitingFemale: yes
Male: yes
180Phase 2France;Belgium;Denmark;Netherlands;Germany;Italy;United Kingdom
4NCT00955279
(ClinicalTrials.gov)
November 20096/8/2009A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With SarcoidosisA Phase 2, Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study Evaluating the Safety and Efficacy of Treatment With Ustekinumab or Golimumab in Subjects With Chronic SarcoidosisSarcoidosisDrug: Placebo;Drug: Golimumab;Drug: UstekinumabCentocor, Inc.NULLCompleted18 Years85 YearsAll173Phase 2United States;Belgium;Denmark;France;Germany;Netherlands;Norway;Romania;United Kingdom;Sweden
5EUCTR2009-010714-30-DE
(EUCTR)
23/10/200908/07/2009A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic SarcoidosisA Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis Chronic sarcoidosis
MedDRA version: 9.1;Level: LLT;Classification code 10039486;Term: Sarcoidosis
Product Name: Golimumab Liquid in prefilled syringe
Product Code: CNTO 148
INN or Proposed INN: golimumab
Other descriptive name: human anti TNF-alpha monoclonal antibody
Product Name: ustekinumab liquid in prefilled syringe
Product Code: CNTO1275
INN or Proposed INN: ustekinumab
Other descriptive name: human anti-IL 12/23 monoclonal antibody
Janssen Biologics B.V.NULLNot RecruitingFemale: yes
Male: yes
180Phase 2France;Belgium;Denmark;Netherlands;Germany;Italy;United Kingdom
6EUCTR2009-010714-30-DK
(EUCTR)
12/10/200917/08/2009A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients with SarcoidosisA Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis Chronic sarcoidosis
MedDRA version: 14.0;Level: PT;Classification code 10039486;Term: Sarcoidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Product Name: Golimumab Liquid in prefilled syringe
Product Code: CNTO 148
INN or Proposed INN: golimumab
Other descriptive name: human anti TNF-alpha monoclonal antibody
Product Name: ustekinumab liquid in prefilled syringe
Product Code: CNTO1275
INN or Proposed INN: ustekinumab
Other descriptive name: human anti-IL 12/23 monoclonal antibody
Janssen Biologics B.V.NULLNot RecruitingFemale: yes
Male: yes
180Phase 2France;United States;Belgium;Romania;Denmark;Netherlands;Germany;Italy;United Kingdom
7EUCTR2009-010714-30-BE
(EUCTR)
28/09/200908/07/2009A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients with SarcoidosisA Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis Chronic sarcoidosis
MedDRA version: 13.1;Level: PT;Classification code 10039486;Term: Sarcoidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Golimumab Liquid in prefilled syringe
Product Code: CNTO 148
INN or Proposed INN: golimumab
Other descriptive name: Human anti TNF-alpha monoclonal antibody
Product Name: ustekinumab liquid in prefilled syringe
Product Code: CNTO1275
INN or Proposed INN: ustekinumab
Other descriptive name: Human anti-IL 12/23 monoclonal antibody
Janssen Biologics B.V.NULLNot RecruitingFemale: yes
Male: yes
180Phase 2France;United States;Belgium;Denmark;Germany;Norway;Netherlands;Italy;United Kingdom
8EUCTR2009-010714-30-GB
(EUCTR)
14/09/200920/07/2009A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic SarcoidosisA Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis Chronic sarcoidosis
MedDRA version: 9.1;Level: LLT;Classification code 10039486;Term: Sarcoidosis
Product Name: Golimumab Liquid in prefilled syringe
Product Code: CNTO 148
INN or Proposed INN: golimumab
Other descriptive name: human anti TNF-alpha monoclonal antibody
Product Name: ustekinumab liquid in prefilled syringe
Product Code: CNTO1275
INN or Proposed INN: ustekinumab
Other descriptive name: human anti-IL 12/23 monoclonal antibody
Janssen Biologics B.V.NULLNot Recruiting Female: yes
Male: yes
180 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noFrance;Belgium;Denmark;Netherlands;Germany;Italy;United Kingdom